ecrin-mdr-crcClinical2018IPD Sharing (as of October 2020): NoLymphoma, Large B-Cell, DiffuseRenal Cell Carcinoma (RCC)Advanced solid tumorMicrosatellite InstabilityCarcinomaTriple Negative Breast NeoplasmsMesotheliomaUrothelial CarcinomaTriple-negative Breast CancerEndometrial NeoplasmsLung NeoplasmsCarcinoma, Merkel CellOvarian CancerGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])Squamous Cell Carcinoma of Head and NeckHepatocellular CarcinomaSmall Cell Lung Cancer (SCLC)Cervical CancerMelanomaSmall Cell Lung CarcinomaDiffuse Large B-cell LymphomaMicrosatellite Instability (MSI)-High Endometrial CancerMerkel Cell CarcinomaMSI-high Colorectal CancerMelanoma (Uveal Melanoma Excluded)Esophageal CancerSquamous Cell Carcinoma of the Head and Neck (SCCHN)Non-small Cell Lung Cancer (NSCLC)Lymphoma, Large B-cell, DiffuseSquamous Cell Carcinoma Of The Head And Neck (scchn)Microsatellite InstabilityCarcinomaTriple Negative Breast NeoplasmsMesotheliomaUrothelial CarcinomaTriple-negative Breast CancerEndometrial NeoplasmsMicrosatellite Instability (msi)-high Endometrial CancerLung NeoplasmsCarcinoma, Merkel CellOvarian CancerGastric Cancer (including Stomach And Gastroesophageal Junction [gej])Advanced Solid TumorHepatocellular CarcinomaCervical CancerMelanomaSmall Cell Lung CarcinomaMelanoma (uveal Melanoma Excluded)Diffuse Large B-cell LymphomaMerkel Cell CarcinomaNon-small Cell Lung Cancer (nsclc)Small Cell Lung Cancer (sclc)Renal Cell Carcinoma (rcc)Squamous Cell Carcinoma Of Head And NeckMsi-high Colorectal CancerEsophageal CancerInterventionalhttps://newmdr.ecrin.org/Study/2273916United States6LAG-3Lymphocyte activation gene (LAG)Relapsed/refractory DLCBLMetastatic solid tumorECRIN MDRCompletedfalseA Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesThe purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.2018-06-152273916NCT03538028